Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Switching From Regimens Consisting of a RTV-Boosted Protease Inhibitor Plus TDF/FTC to a Combination of Raltegravir Plus Nevirapine and Lamivudine in HIV Patients With Suppressed Viremia and Impaired Renal Function (RANIA Study) (Pilot Study) Protocol MK-0518-284-02

Next Previous
Search
Trial Profile

Switching From Regimens Consisting of a RTV-Boosted Protease Inhibitor Plus TDF/FTC to a Combination of Raltegravir Plus Nevirapine and Lamivudine in HIV Patients With Suppressed Viremia and Impaired Renal Function (RANIA Study) (Pilot Study) Protocol MK-0518-284-02

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 12 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lamivudine (Primary) ; Nevirapine (Primary) ; Raltegravir (Primary) ; Atazanavir/ritonavir; Darunavir/ritonavir; Emtricitabine/tenofovir disoproxil fumarate; Lopinavir/ritonavir
  • Indications HIV infections
  • Focus Therapeutic Use
  • Acronyms RANIA
  • Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Italia

    • Most Recent Events

    • 06 Sep 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Aug 2017.
    • 01 Dec 2015 Planned End Date changed from 1 Jul 2017 to 1 Aug 2017 as reported by ClinicalTrials.gov.
    • 07 Oct 2015 Planned End Date changed from 1 Oct 2017 to 1 Jul 2017, as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top